End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
316,500 KRW | -0.63% | +0.96% | -10.21% |
May. 01 | Hanmi Pharm Q1 Profit Surges 27.5%, Sales Up 11.8% | MT |
Mar. 19 | Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The firm trades with high earnings multiples: 25.2 times its 2024 earnings per share.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.21% | 2.9B | B | ||
+19.27% | 43.18B | B- | ||
+21.27% | 23.23B | B+ | ||
+15.11% | 14.6B | - | ||
+38.36% | 11.5B | B | ||
-8.43% | 6.79B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+10.21% | 5.31B | B+ | ||
-2.27% | 4.81B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A128940 Stock
- Ratings Hanmi Pharm. Co., Ltd.